Trial Profile
Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Single Center, Open-label, Parallel-group, Phase I Trial
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2016
Price :
$35
*
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Apr 2016 Protocol amended as time frame for primary endpoints changed from upto 10 days - day 4 as reported by ClinicalTrials.gov.
- 08 Apr 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Jan 2014 Status changed to completed according to ClinicalTrials.gov .